Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03496636
Other study ID # PRO17120172
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date September 1, 2027

Study information

Verified date May 2023
Source University of Pittsburgh
Contact Rachel Neelley
Phone 412-641-7475
Email fertilitypreservation@upmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO08050491). The objective of this study is to study the efficacy and safety of autologous tissue transplantation in patients diagnosed with primary ovarian insufficiency after chemotherapy and/or radiation treatments.


Description:

This investigation involves patient enrollment, thaw and surgical transplantation of previously collected cryopreserved ovarian cortical tissue, a series of follow-up assessments during the first 2 years after transplantation and an annual survey after year 2. Screening visit (standard fertility consultation): 1. The subject will complete a medical and reproductive history to document menstrual function and suitability for pregnancy. 2. The subject will have standard fertility testing (including but not limited to serum Follicle Stimulating Hormone (FSH), Estradiol (E2), and Anti-Mullerian Hormone (AMH), luteinizing hormone (LH), testosterone and progesterone). 3. Vaginal ultrasound will be performed for measures of ovarian volume and antral follicle counts. 4. A pregnancy test will be performed to rule out pregnancy. 5. Each potential subject will undergo a comprehensive fertility consult including counseling regarding the extent to which participation in this study might be of ultimate benefit. Alternatives to participation include: continuing to try to conceive on her own, use of donor oocytes or embryos, or adoption. 6. The subject will have to obtain clearance from her oncologist and will be counseled by a reproductive endocrinologist to determine whether she is healthy enough to consider pregnancy and to discuss the potential risks and benefits of the study. Visit #1 - pre-op visit (can be combined with initial screening visit): Eligible subjects will be consented by the study physician and complete the same infectious disease testing as was performed at the time of ovarian tissue freezing (including but not limited to HIV 1&2, HTLV 1&2, Hepatitis B, Hepatitis C, syphilis, chlamydia, gonorrhea, CMV, West Nile virus). The subjects will also complete Fertility quality of life survey (FertiQoL). FertiQoL is a validated measure of quality of life in people experiencing fertility problems. Only after confirming eligibility, obtaining informed consent and completing baseline measures, ovarian tissue thawing and transplantation will be performed. Visit #2 - Ovarian tissue transplantation: At the time of ovarian tissue thawing, an outpatient laparoscopy (or minilaparotomy if the patient is not deemed to be a good candidate for laparoscopic surgery) will be performed under general anesthesia. Ovarian cortical tissue will be transplanted within the pelvis according to the most effective available techniques. Visit #3: Post-operative assessment: Within six weeks of transplant, a postoperative follow-up assessment will be conducted to ensure adequate patient recovery and emotional well-being. Blood tests (including but not limited to serum FSH, E2, and AMH, LH, testosterone and progesterone), pelvic ultrasound and FertiQoL survey, will be conducted to assess reproductive hormone levels, menstrual function, complications from surgery, pregnancy, medical and medication history, and cancer relapse. Referral to the clinical counselor may be made, if indicated. Visits #4, #5, #6, #7 and #8 at 3, 6, 9, 12 and 24 months post-op: A series of 5 additional follow-up assessments will be conducted during the first 2 years after transplant with Reproductive Endocrinology and Infertility to assess reproductive hormone levels, menstrual function, complications from surgery, pregnancy, changes in medical and medication status, and cancer relapse. A visit may be added at the time menstruation is restored if this occurs between regularly scheduled visits. At each follow up visit hormone testing is performed, vaginal ultrasound and FertiQoL survey will be administered. Additional clinical follow-up and testing may be determined in consultation with the subject's oncologist. Annual Survey: Starting year 3 post-transplantation, each subject will be surveyed annually. The survey is voluntary and confidential and will be conducted by scripted phone interview or self-administered survey through secure email. The survey will include questions about menstrual/pregnancy history, new diagnoses or treatments, and feelings about participating in the study. Detailed information about pregnancy and birth outcomes will be collected by a combination of survey and chart review. Outcome data including remission, relapse or death, will be collected. Contact information will also be updated.


Recruitment information / eligibility

Status Recruiting
Enrollment 5
Est. completion date September 1, 2027
Est. primary completion date September 1, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Previously cryopreserved ovarian tissue - Ovarian insufficiency and/or candidate for pregnancy - Good health - Oncologist's clearance Exclusion Criteria: - Patients considered to be high risk for surgical complications - Women with contraindication for pregnancy if goal is to achieve pregnancy - Women positive for the BRCA mutations - Women with a history of leukemia, ovarian cancer or a cancer that likely involved ovaries at the time of ovarian tissue collection - Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent - Current pregnancy

Study Design


Intervention

Procedure:
Ovarian tissue transplant
Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy

Locations

Country Name City State
United States Magee-Womens Hospital Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in reproductive hormone levels after ovarian tissue transplant Measure of reproductive hormone levels (FSH, AMH, LH E2 and others) to detect graft function 1,3,6,9,12 and 24 months post-transplantation
Primary Return of regular monthly menstrual cycles Onset of regular monthly menstrual cycles after transplantation would indicate graft function. This needs to be analyzed at multiple time points to assess if regular monthly menstrual cycles have ceased, which could indicate graft failure. Through study completion, up to 15 years
Primary Achievement of successful pregnancy, measured by live birth Indicates recovery of ovarian function Through study completion, up to 15 years
Secondary Cancer recurrence as determined by patient's oncologist Indicates cancer recurrence Through study completion, up to 15 years
Secondary Surgical complications of ovarian tissue transplantation Infection, hospital readmission, re-operation 1,3,6,9,12 and 24 months post-transplantation
Secondary Fertility quality of life (FertiQoL) survey results Measure quality of life in individuals experiencing fertility problems 1,3,6,9,12 and 24 months post-transplantation
See also
  Status Clinical Trial Phase
Completed NCT06239051 - Greening the Humanitas Fertility Center: How to Build a More Sustainable Medical Daily Routine
Recruiting NCT05179993 - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT03737253 - Hormone Evaluation in Artificial Reproductive Technology Phase 4
Not yet recruiting NCT02237781 - Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins Phase 2/Phase 3
Not yet recruiting NCT02237755 - Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. Phase 2/Phase 3
Completed NCT01477073 - Multiple Dose FSH-GEX(TM) in Healthy Volunteers Phase 1
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06098495 - Looking for a Blood Epigenetic Signature to Predict Female Infertility
Completed NCT03998553 - Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women N/A
Completed NCT05189145 - Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles N/A
Recruiting NCT05050747 - Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Completed NCT01620346 - Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age N/A
Completed NCT00315029 - Patient-Centered Implementation Trial for Single Embryo Transfer N/A
Recruiting NCT03080584 - Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients N/A
Not yet recruiting NCT05106712 - Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women N/A
Recruiting NCT06041204 - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism N/A
Completed NCT01604044 - Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial. Phase 1
Completed NCT02328924 - There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols? Phase 4
Completed NCT04019899 - Myo-inositol and Vitamin D3 During IVF N/A